EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center

Mathias Jachs iD, Raphael Sauberer, Alexander Stiegler, Anton Dechêne, Raphael Tazreiter, Lukas Hartl, David Bauer, Lorenz Balcar iD, Robert Strassl, Mattias Mandorfer iD, Michael Trauner, Petra Munda und 2 weitere

United European Gastroenterology Journal · 2023

DOI: 10.1002/ueg2.12376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Mathias Jachs und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Treatment indications for chronic hepatitis B (CHB) differ among recommendations by European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD) and World Health Organization (WHO). We aimed to assess treatment eligibility and linkage to therapy at a large tertiary care center.

Methods

All CHB patients who were evaluated for treatment at the Vienna General Hospital between January 2010 and December 2020 were retrospectively included. Clinical, virological, and long‐term treatment efficacy data were analyzed.

Results

A total of 751 CHB patients were included (53.3% male; median age: 39.5 years; HBeAg‐positive: 10.8%). The median Hepatitis B Virus (HBV)‐DNA and HBsAg levels were 569 (68–11,750) IU/mL and 3467.65 (620.05–11,935.43) IU/mL, respectively. Overall, 9.2% of patients had severe fibrosis/cirrhosis, and 5.7% were coinfected with hepatitis D virus (HDV), which was highly prevalent in cirrhosis. According to the recent EASL nomenclature, 3.2% of patients had HBeAg‐positive chronic infection, 7.6% had HBeAg‐positive chronic hepatitis, 58.9% had HBeAg‐negative chronic infection, and 30.4% had HBeAg‐negative chronic hepatitis. At the time of evaluation, 36.4% had HBV‐DNA >2000 IU/mL, and 37.3% showed alanine aminotransferase >40 U/L. Ultimately, 26.9% (EASL), 29.0% (AASLD) and 23.4% (WHO) met the treatment criteria. Treatment was initiated in most patients, mainly with tenofovir (61.8%) or entecavir (34.9%). Treatment efficiently suppressed HBV‐DNA in all patients; however, HBsAg loss was observed only in 2.8% at 5 years of therapy.

Conclusions

Severe fibrosis/cirrhosis was found in 9.2% of CHB patients at presentation, and 23.4%–29.5% met current treatment recommendations with a high treatment uptake of 79.8%–89.2% among eligible patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHepatitis B, ChronicHumansMaleAdultFemaleHepatitis B e AntigensRetrospective StudiesDNA, ViralTertiary Care CentersPersistent InfectionLiver CirrhosisAntiviral Agents

Stichwörter der Autor:innen

chronic hepatitis Bentecavirhepatitis B infectionhepatitis D coinfectionlinkage to careliver cirrhosistenofovirtreatment uptake

Substanzen

Hepatitis B Surface AntigensHepatitis B e AntigensDNA, ViralAntiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Clinical Virology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Mathias Jachs, Lorenz Balcar, Mattias Mandorfer, Thomas Reiberger

Zitieren

APA

Jachs, M., Sauberer, R., Stiegler, A., Dechêne, A., Tazreiter, R., Hartl, L., Bauer, D., Balcar, L., Strassl, R., Mandorfer, M., Trauner, M., Munda, P., Ferenci, P., & Reiberger, T. (2023). Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12376

Vancouver

Jachs M, Sauberer R, Stiegler A, Dechêne A, Tazreiter R, Hartl L, et al. Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12376

BibTeX
@article{Jachs2023,
  author = {Jachs, Mathias and Sauberer, Raphael and Stiegler, Alexander and Dechêne, Anton and Tazreiter, Raphael and Hartl, Lukas and Bauer, David and Balcar, Lorenz and Strassl, Robert and Mandorfer, Mattias and Trauner, Michael and Munda, Petra and Ferenci, Peter and Reiberger, Thomas},
  title = {Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center},
  journal = {United European Gastroenterology Journal},
  year = {2023},
  doi = {10.1002/ueg2.12376}
}
Kostenlos starten →